James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

2 New Funds Add a New Twist to Biotech Stocks

Calling all fans and followers of breakthrough biotech stocks! Stop searching for the next big winner and just own one of these new biotech ETFs instead.

3 Stocks With Plunging Prices

Here's why Agios Pharmaceuticals Inc (AGIO), Zulily Inc (ZU) and Aruba Networks, Inc. (ARUN) are three of today's worst stocks.

5 Healthcare Stocks to Buy

While it's unlikely healthcare stocks will lead the market two years in a row, there are still plenty of great healthcare stocks to buy.

Why Ocwen Financial, Gilead Sciences and United States Steel Are 3 of Today’s Worst Stocks

United States Steel, Ocwen Financial and Gilead Sciences dipped into the red ink on an otherwise bullish day. Here's what happened.

Why Foot Locker, Hasbro, and EQT Corporation Are 3 of Today’s Worst Stocks

EQT Corporation, Foot Locker and Hasbro couldn't win for losing today. Here's the deal.